Scrip is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
| Other Products: In Vivo | Medtech Insight | Pink Sheet | Rose Sheet | Report Store |  |
This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183
Printed By
This article was originally published in Start Up
With new approaches in development that add or subtract genetic material to viruses, or arm them with immune-boosting proteins, oncolytic viruses may become the next modality for treating cancer. Several smaller companies and their backers – as well as those who have yet to invest in the space – eagerly await results from Amgen’s Phase III program OncoVex.
| Table |
|---|
Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst
Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.
All fields are required.
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.
